title: Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients.
abstract: Differences in engraftment potential of hematopoietic stem cells (HSCs) in distinct phases of cell cycle may result from the inability of cycling cells to home to the bone marrow (BM) and may be influenced by the rate of entry of BM-homed HSCs into cell cycle. Alternatively, preferential apoptosis of cycling cells may contribute to their low engraftment potential. This study examined homing, cell cycle progression, and survival of human hematopoietic cells transplanted into nonobese diabetic severe combined immunodeficient (NOD/SCID) recipients. At 40 hours after transplantation (AT), only 1% of CD34(+) cells, or their G(0) (G(0)CD34(+)) or G(1) (G(1)CD34(+)) subfractions, was detected in the BM of recipient mice, suggesting that homing of engrafting cells to the BM was not specific. BM of NOD/SCID mice receiving grafts containing approximately 50% CD34(+) cells harbored similar numbers of CD34(+) and CD34(-) cells, indicating that CD34(+) cells did not preferentially traffic to the BM. Although more than 64% of human hematopoietic cells cycled in culture at 40 hours, more than 92% of cells recovered from NOD/SCID marrow were quiescent. Interestingly, more apoptotic human cells were detected at 40 hours AT in the BM of mice that received xenografts of expanded cells in S/G(2)+M than in recipients of G(0)/G(1) cells (34.6% +/- 5.9% and 17.1% +/- 6.3%, respectively; P <.01). These results suggest that active proliferation inhibition in the BM of irradiated recipients maintains mitotic quiescence of transplanted HSCs early AT and may trigger apoptosis of cycling cells. These data also illustrate that trafficking of transplanted cells to the BM is not selective, but lodgment of BM-homed cells may be specific.
authors.affiliation: Department of Medicine, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, 46202-5121, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Jetmore
authors.forename: P Artur
authors.initials: PA
authors.lastname: Plett
authors.forename: Xia
authors.initials: X
authors.lastname: Tong
authors.forename: Frances M
authors.initials: FM
authors.lastname: Wolber
authors.forename: Robert
authors.initials: R
authors.lastname: Breese
authors.forename: Rafat
authors.initials: R
authors.lastname: Abonour
authors.forename: Christie M
authors.initials: CM
authors.lastname: Orschell-Traycoff
authors.forename: Edward F
authors.initials: EF
authors.lastname: Srour
mesh_terms: D000818:Animals; D018952:Antigens, CD34; D001854:Bone Marrow Cells / Q000166:cytology; D002453:Cell Cycle / Q000502:physiology*; D002465:Cell Movement; D006085:Graft Survival / Q000502:physiology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000502:physiology; D006801:Humans; D007399:Interphase / Q000502:physiology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D013154:Spleen / Q000166:cytology; D019172:Transplantation Conditioning; D014183:Transplantation, Heterologous
chemical_list: D018952:Antigens, CD34